All In Biotech

Free tool

FAERS Monitor: Sotylize

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 205108 or its brand name (Sotylize, Sotalol Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

2,530

Serious

2,120

84% of reports

Hospitalization

1,129

Death reported

255

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • atrial fibrillation171
  • electrocardiogram qt prolonged148
  • drug ineffective144
  • hypotension123
  • dyspnoea117
  • bradycardia112
  • dizziness110
  • drug interaction99
  • nausea93
  • fatigue92
  • fall86
  • acute kidney injury72
  • off label use72
  • ventricular tachycardia72
  • asthenia63

Reports by year received

View as table
YearReports
200446
200531
2006127
2007234
200830
2009123
201030
201179
2012107
201357
201466
201555
201676
201796
2018126
2019147
2020110
202195
2022140
2023151
2024195
2025253
2026156

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,629 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
ventricular tachycardiaSignal7236.429.02,434
electrocardiogram qt prolongedSignal14834.329.44,747
bradycardiaSignal11217.614.71,737
atrial fibrillationSignal17114.612.62,163
drug interactionSignal995.24.3333
hypotensionSignal1235.14.3405
acute kidney injurySignal723.93.1154
fallSignal862.11.752
dizziness1101.81.542
dyspnoea1171.71.435
asthenia631.41.17
fatigue921.00.80
nausea931.00.80
drug ineffective1440.90.81
off label use720.70.511

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.